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Available online 2 March 2016Background: Non-alcoholic steatohepatitis (NASH) is often accompanied by liver ﬁbrosis, which can progress to
cirrhosis; C-C chemokine receptors type 2 and 5 (CCR2/CCR5), which mediate interactions driving inﬂammation
and ﬁbrosis, are promising treatment targets. Cenicriviroc (CVC), a dual-CCR2/CCR5 antagonist, has potent anti-
inﬂammatory and antiﬁbrotic activity in animal models; in HIV-positive subjects it reduced soluble CD14 levels,
aspartate aminotransferase-to-platelet count ratio index, and non-invasive hepatic ﬁbrosis risk scores; favorable
tolerability was demonstrated in ~600 subjects. Efﬁcacy and safety of CVC 150 mg for treating NASH with liver
ﬁbrosis are being evaluated over 2 years (primary endpoint at Year 1 [Y1]).
Design: Phase 2b, randomized, double-blind, placebo-controlled,multinational study (CENTAUR;NCT02217475).
Adults with histological evidence of NASH, non-alcoholic fatty liver disease activity score (NAS) ≥ 4, and liver ﬁ-
brosis (stages 1–3 NASH clinical research network system) enrolled. Subjects have increased risk of progression
to cirrhosis due to ≥1 characteristic: type 2 diabetes; body mass index N 25 kg/m2 with ≥1 feature of metabolic
syndrome; bridging ﬁbrosis and/or NAS ≥ 5. Liver biopsy evaluation at Screening, Y1, and Year 2 (Y2).
Objectives:Assess histologic improvement (≥2-point inNASwith ≥1-point improvement in N1 category)without
worsening of ﬁbrosis at Y1 (primary); evaluate complete NASH resolution without worsening of ﬁbrosis at Y2
(key secondary).
Discussion: CENTAUR is the ﬁrst prospective study evaluating an oral agent exclusively enrolling subjects with
NASH and liver ﬁbrosis, with increased risk of developing cirrhosis. It will compare shorter versus longer CVC
treatment and assess correlations between decreased inﬂammation and ﬁbrosis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Non-alcoholic fatty liver disease (NAFLD) is commonly associated
with obesity-related disorders (e.g. type 2 diabetes mellitus [T2DM]
and metabolic syndrome) [1–5]. Approximately 10–20% of subjects
with NAFLD have a progressive form, non-alcoholic steatohepatitis
(NASH) [6], deﬁned by the presence of steatosis, hepatocellular balloon-
ing, and lobular inﬂammation. NASH is typically associatedwith inﬂam-
mation and ﬁbrosis [1,2,6], which can progress to cirrhosis, end-stage
liver disease, and hepatocellular carcinoma [6–9]. Although ﬁbrosis iss, Icahn School of Medicine at
10029, USA.
n).
. This is an open access article undernot always present in NASH, ﬁbrosis severity is linked to long-term out-
comes [6,10]. NAFLD and NASH prevalences are increasing worldwide,
associated with a rise in obesity-related disorders [6,11,12]. Globally,
the prevalence rate of NAFLD is 6–35%, with a median of 20% [11]. Sys-
tematic reviews based on liver biopsy data suggest that approximately
3–5% of the US population have NASH [11]; comparable prevalences
are expected in Europe and the Middle East [6,12]. Furthermore, a lon-
gitudinal study reported that 84.9% of patients with borderline or deﬁ-
nite NASH in the USA, Europe and Thailand had liver ﬁbrosis (stages
1–4) [10]. Despite its rising prevalence, there are currently no approved
treatments for NASH.
The C-C chemokine receptor types 2 and 5 (CCR2 and CCR5), and
their respective ligands, C-C chemokine ligand types 2 (CCL2/monocyte
chemoattractant protein-1 [MCP-1]) and 5 (CCL5/RANTES), arethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patocyte injury, resident liver macrophages (Kupffer cells) secrete
CCL2; this promotes monocyte recruitment and migration to the liver,
where they mature into pro-inﬂammatory macrophages [19,20]. Mac-
rophages express pro-inﬂammatory cytokines, which activate hepatic
stellate cells (HSCs) to promote their survival, while stimulating colla-
gen production or ﬁbrogenesis [21–24]. CCR2 and CCR5 mediate the
intrahepatic immune-cell interactions that promote activation and mi-
gration of Kupffer cells and HSCs (Fig. 1) [13–16]. Activation of inﬂam-
matory cells and upregulation of several soluble inﬂammatory
mediators, including CCL2 and CCL5, are features of NASH [25]. In ani-
mal studies of hepatic ﬁbrosis,micewith a targeted deletion or pharma-
cological inhibition of CCR2 [16,17,19,20] or CCR5 [15,18] display lower
immune-cell activation and reduced liver ﬁbrosis; therefore, CCR2 and
CCR5 are promising targets for treatment of NASH.
Cenicriviroc (CVC) is a novel, oral, dual CCR2/CCR5 antagonist with
nanomolar potency against both receptors, and a long plasma half-life
(30–40 h in humans). Phase 2 Studies 201 (NCT01092104) and 202
(NCT01338883), conducted in human immunodeﬁciency virus (HIV)-in-
fected subjects, have also shown CCR2 blockade, associated with an in-
crease in CCL2 levels, and CCR5 blockade, demonstrated by reduction in
HIV-1 RNA levels [26,27]. Antiﬁbrotic effects of CVC have been demon-
strated in multiple animal models of liver, as well as in kidney, ﬁbrosis
[28,29]. A post hoc analysis of Study 202 revealed improvements in solu-
ble cluster of differentiation 14 (sCD14) and ﬁbrosis scores in subjects
treated with CVC [27,30,31]. The proportion of subjects with aspartate
aminotransferase-to-platelet count ratio index (APRI) score ≥ 0.5 and
non-invasive hepatic ﬁbrosis risk (FIB-4) score ≥ 1.45 decreased by 75%
and 73%, respectively, between Baseline and Week 24; these decreases
were maintained at Week 48 [32]. Additionally, the mean enhanced
liver ﬁbrosis (ELF) test index in subjects treated with CVC decreasedFig. 1. Inﬂammatory response to hepatocyte injury leading to ﬁbrogenesis [13–16,19–24]. CCL2,
receptor type 5; DAMPs, danger-associated molecular patterns; ECM, extracellular matrix;
associated molecular patterns; PDGF, platelet-derived growth factor; TGF-β, transforming growfrom 10.53 ± 2.12 to 8.28 ± 0.88 (p b 0.0001) by Week 48 [31]. CVC
has a favorable safety proﬁle and was well tolerated in approximately
600 subjects, including those with mild or moderate hepatic impairment
(Child–PughA and B) [26,27,33]. Therefore, CVC is an attractive candidate
for the treatment of NASH and liver ﬁbrosis by antagonism of CCR2/CCR5
receptors. CENTAUR (NCT02217475) will examine the efﬁcacy, pharma-
cokinetics (PK), and safety of CVC for the treatment of NASH in adults
with liver ﬁbrosis, for which CVC has received Fast Track designation by
the US Food and Drug Administration (FDA).
2. Methods
2.1. Study design
CENTAUR is a Phase 2b, randomized, double-blind, placebo-
controlled, multinational study that will be conducted in adult subjects
with NASH and liver ﬁbrosis in 11 countries across the USA, Europe, and
Asia-Paciﬁc. The study was planned to recruit 252 adults; a total of 289
adults were enrolled due to increased screening efforts once all global
study sites were activated. The studywill evaluate the efﬁcacy and safe-
ty of CVC 150 mg over 2 years of treatment, with a primary endpoint at
Year 1. The study design is shown in Fig. 2.
2.2. Study rationale
CVC is expected to have anti-inﬂammatory and antiﬁbrotic activities
due to its dual antagonism of CCR2/CCR5 receptors. Themechanisms by
which CVC may prevent inﬂammation and ﬁbrosis in NASH are
decreased recruitment, migration, and inﬁltration of pro-inﬂammatory
monocytes to the site of liver injury induced by activated Kupffer cells,
mainly via CCR2 antagonism. This consequently reduces the numberC-C chemokine ligand type 2; CCR2, C-C chemokine receptor type 2; CCR5, C-C chemokine
IL-1β, interleukin 1β; MCP-1, monocyte chemoattractant protein-1; PAMPs, pathogen-
th factor beta; TNF, tumor necrosis factor.
Fig. 2. Study design for CENTAUR. aN= 252, planned sample size; N= 289 enrolled. CVC, cenicriviroc; QD, once daily.
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chronic liver inﬂammation and downregulating the production of
proﬁbrotic cytokines, such as transforming growth factor beta 1 (TGF-
β1). TGF-β1 promotes the transdifferentiation of HSCs to collagen-
synthesizing myoﬁbroblasts and the production of tissue inhibitors of
metalloproteinases, which inhibit themetalloproteinase-mediated deg-
radation of extracellular matrix components [34]. In addition, CCR5 and
CCL5mediate HSCmigration and proliferation, aswell as ‘cross-talk’ be-
tween HSCs and leukocytes during ﬁbrogenesis [14]. Therefore, disrup-
tion of CCR2 and CCR5 signaling pathways is expected to provide anti-
inﬂammatory and antiﬁbrotic beneﬁts.
2.3. Endpoint rationale
A 2011 meeting sponsored by the American Association for the
Study of Liver Diseases (AASLD), discussed key endpoints and speciﬁc
trial design issues relevant for treatment trials forNASH [35]. Itwas con-
cluded that the primary endpoint should be measurable, sensitive to
change, clinically meaningful, and be able to be quantiﬁed consistently.
Two histology-based primary endpoints were recommended: “a mini-
mum of 2 point improvement in NAFLD activity score (NAS) with at
least one point improvement inmore than one category and noworsen-
ing of ﬁbrosis” and “resolution of steatohepatitis with no worsening ofFig. 3. Efﬁcacy endpoints for CENTAUR. α-SMA, α-smooth muscle actin; APRI, aspartate ami
collagen proportionate area; CRN, clinical research network; CVC, cenicriviroc; ELF, enhance
magnetic resonance elastography; NAS, non-alcoholic fatty liver disease activity score; NASH
ultrasound transient elastography.ﬁbrosis” [35]. More recently, a summary of a 2013 joint AASLD–FDA
workshop proposed a similar endpoint to the latter: the “reversal (i.e.
resolution) of steatohepatitis without progression to advanced ﬁbrosis
(stages 3–4)” [36]. This suggests that it could be an acceptable surrogate
endpoint suitable for both Phase 2b and 3 trials that enroll patients with
NASH and evidence of early ﬁbrosis, and for FDA accelerated approval
under Subpart H [36]. The advantage of NAS is that it is quantiﬁable
and relatively more reproducible than the diagnosis of steatohepatitis,
and remains a suitable endpoint to assess histological disease activity
and provide robust evidence of early treatment effects. Importantly, it
is expected that reversal of steatohepatitis would reduce the risk of de-
veloping cirrhosis [35,36]. This is supported by recent randomized clin-
ical trials evaluating NASH agents, where antiﬁbrotic effects have also
been observed in addition to resolution of NASH [37,38]. The design of
CENTAUR and its key endpoints are aligned with these recommenda-
tions. Speciﬁcally, the primary endpoint of CENTAUR, “drop in NAS by
≥2 with at least a 1-point improvement in more than 1 category and
with no concurrent worsening of ﬁbrosis stage (Year 1)” was also
used in the PIVENS (NCT00063622) and FLINT (NCT01265498) studies
[37,39]. The key secondary endpoint of CENTAURwill be “complete res-
olution of NASH (histopathologic interpretation of no fatty liver disease
or simple or isolated steatosis with no steatohepatitis) with nonotransferase-to-platelet count ratio index; ARFI, acoustic radiation force impulse; CPA,
d liver ﬁbrosis test; FIB-4, non-invasive hepatic ﬁbrosis risk score; MRE, 2-dimensional
, non-alcoholic steatohepatitis; NFS, non-alcoholic fatty liver disease ﬁbrosis score; TE,
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sion of NASH Clinical Research Network [CRN] ﬁbrosis stage) at Year
2” (Fig. 3).
In addition, the consensus at the AASLD meeting was that trials
assessing improvement in ﬁbrosis should last at least 1–2 years, since
it is assumed that improvement in ﬁbrosis occurs only after other fea-
tures of NASH are improved (e.g. hepatocellular ballooning and lobular
inﬂammation) [35]. There are currently limited data to establish the op-
timal treatment duration of NASH. Findings from the PIVENS and FLINT
studies suggest that improvements in the NAS score can be observed
relatively early but that longer-term treatment may be required to
achieve complete NASH resolution [37,39]. Furthermore, 24-week
follow-up after treatment completion in these two studies suggest a re-
turn to baseline for hepatic andmetabolic effects, indicating that chron-
ic treatment is likely to be required for this condition. These
considerations have been incorporated into CENTAUR study design
and analysis, which will take place over a 2-year duration and include
liver biopsies collected at Years 1 and 2. These two time points will
allow for the assessment of the beneﬁts of shorter versus longer treat-
ment intervention for subjects on CVC, and provide natural history
data for subjects on placebo. Several key efﬁcacy endpoints will be
assessed at Years 1 and 2 due to the differences in timing at which
these endpoints are expected to be reached. Analysis of the primary
endpointwill take place at Year 1, as it is expected that an improvement
in NAS should occur relatively early during CVC treatment, due to the
rapid and sustained blockade of CCR2 and CCR5 [26,27]. As improve-
ment in ﬁbrosis may be delayed in the setting of chronic liver disease
[35], analysis of the key secondary endpoint will take place at Year 2
to assess longer-term effects on improvement in ﬁbrosis and complete
resolution of NASH.
At Year 1, all efﬁcacy endpoints will compare results from Arm A
(CVC 150 mg) with pooled results from Arms B and C (placebo;
Fig. 2). After Year 1, subjects in Arm B will cross over from placebo to
CVC, which will allow more patients to receive investigational treat-
ment for NASH, thereby increasing their likelihood of receiving active
drug during this 2-year study that requires a total of three serial biop-
sies. This is expected to increase motivation of subjects to participate
and to remain in the study, while still maintaining placebo control
throughout to evaluate the efﬁcacy endpoints, and providemore robust
evaluation of the efﬁcacy and safety of CVC. Since Arm B subjects will
cross over from placebo to CVC after Year 1, the main efﬁcacy compari-
sons at Year 2 will include Arm A (CVC 150mg) versusArm C (placebo).
Given that bothArms A and Cwill remain on assigned treatment for a 2-
year duration, with liver biopsies obtained at Years 1 and 2, this will
allow for evaluation of shorter versus longer CVC treatment (Arm
A) even though the total number of placebo subjects at Year 2will be re-
duced. Other comparisons pooling Year 2 results from Arms A and B
(CVC 150mg) to Arm C (placebo) will also bemade to assess overall ef-
ﬁcacy of CVC treatment.
Other endpoints (Fig. 3) will include improvement in histologic ﬁ-
brosis stage (NASH CRN and Ishak scoring systems); morphometric
quantitative collagen (collagen proportionate area); HSC activation
marker (α-smooth muscle actin [α-SMA]); biomarkers of hepatocyte
apoptosis (CK-18 [caspase-cleaved and total]); non-invasive markers
of hepatic ﬁbrosis (APRI, FIB-4, hyaluronic acid, FibroTest [FibroSure],
NAFLD ﬁbrosis score [NFS], and ELF); and non-invasive liver imaging
methods (e.g. ultrasound transient elastography [TE], 2-dimensional
magnetic resonance elastography [MRE], acoustic radiation force im-
pulse [ARFI]). All efﬁcacy endpoints will be evaluated at Years 1 and 2,
to allow comparisons between shorter and longer treatment intervals
with CVC.
2.4. Dosing rationale
A dose of CVC 150 mg (new, improved single-tablet formulation)
was selected for CENTAUR to ensure that plasma exposures aresufﬁcient to provide near maximal antagonism of CCR2/CCR5. This
was based on the CCR2/CCR5 concentration-dependent antagonism
that had been observed in in vitro and ex vivo studies with CVC, as
well as in extensive PK/pharmacodynamic (PK/PD) analyses from two
Phase 2 HIV clinical studies of CVC. These two studies conﬁrmed that
doses of 100 mg and 200 mg (previous formulation) were effective
and well tolerated, resulting in potent CCR2 and CCR5 antagonism [26,
27]. Phase 1 studies have indicated that CVC plasma exposures may be
higher in non-HIV-infected healthy subjects than in HIV-infected sub-
jects [27,40]. PK data from these studies suggest that CVC 150 mg
(new formulation) should provide exposures in subjects with NASH
and liver ﬁbrosis that are comparable to those of CVC 200 mg (previous
formulation) in HIV-infected subjects. This choice of dose is further sup-
ported by PK ﬁndings from two multidose Phase 1 studies evaluating
CVC 150 mg either in healthy subjects [41], or in patients with mild
(Child–Pugh A) to moderate (Child–Pugh B) liver impairment [33].
2.5. Study objectives
The objectives of CENTAUR are shown in Table 1. The primary objec-
tive of this study is to assess hepatic histologic improvement in NAS
after 1 year of CVC treatment versus placebo relative to Screening biop-
sy. This improvement is deﬁned by aminimum2-point improvement in
NAS, with at least a 1-point improvement in more than one category.
There must also be no worsening of NASH CRN ﬁbrosis stage to be con-
sidered as improvement of NAS. The key secondary objective of this
study is to evaluate the complete resolution ofNASHwith no concurrent
worsening of ﬁbrosis stage after 2 years of CVC treatment versus
placebo.
2.6. Sample size
Based on a two-sided alpha of 0.05 and a 1:1 randomization, the
planned sample size of 252 subjects (equal allocation of 126 subjects
to the CVC treatment and placebo groups) was expected to provide at
least 80% power to demonstrate superiority of CVC versus placebo
with respect to the primary endpoint at Year 1 (Fig. 2). These sample-
size calculations assumed a 20% response rate for placebo, based on re-
sults from the PIVENS and FLINT studies, and a 36% response rate for
CVC treatment at the end of Year 1, using PROC POWER in SAS version
9.3 (SAS Institute Inc., USA) with the two-sample Fisher's exact test op-
tion. Due to a combination of high unmet need and investigator interest,
the study over-enrolled by 15%, with a total of 289 subjects (approxi-
mately 145 subjects on CVC and placebo in Year 1). Hence, a revised
power calculation table is provided, with 140 subjects receiving CVC
and placebo during Year 1 (Table 2). Both updated and original sample
size calculations assumed approximately 15% subject attrition over the
2-year duration, where a missing biopsy result is treated as non-
response (by comparison, 13% of randomized subjects in PIVENS [39]
were missing their post-treatment biopsy). Revised calculations were
consistent with original powering assumptions, thereby supporting
their robustness.
3. Study procedures
3.1. Recruitment and screening
CENTAURwill be conducted according to all applicable laws and reg-
ulations, and an ethics review was conducted according to the Declara-
tion of Helsinki (October 2008), as described in the International
Conference on Harmonisation E6 Guideline for Good Clinical Practice
and/or local laws. Before enrollment, informed consent to participate
in the studywas obtained fromeach subject. The protocol and any infor-
mation supplied to the subject to gain informed consent was reviewed
and approved by a qualiﬁed Institutional Review Board (IRB)/
Table 1
CENTAUR study objectives and procedures.
Study timepoint (months)
Study objectives 3 6 12 15 18 24
Primary objective
• Hepatic histological improvement in NAS at Year 1 relative to Screening biopsy (≥2-point improvement in NAS
with at least a 1-point improvement in more than one category) with no concurrent worsening of ﬁbrosisa (Arm A
versus Arms B and C)
X
Key secondary objective
• Complete resolution of NASHb with no concurrent worsening of ﬁbrosisa at Year 2 (Arm A versus Arm C) X
Other secondary objectives
• Complete resolution of NASHb with no concurrent worsening of ﬁbrosisa at Year 1 (Arm A versus Arms B and C) X
• Assessment of CVC safety and tolerability over Years 1 and 2 Continuous
• Plasma PK of CVC in a population PK analysisc X X X X X X
• Hepatic histological improvement in NAS at Year 2 relative to Screening biopsy (2-point improvement in NAS with
at least a 1-point improvement in more than one category) with no concurrent worsening of ﬁbrosisa (Arm A
versus Arm C)
X
• Change in CPA on liver biopsy to evaluate efﬁcacy of CVC versus placebo X X
• Improvement in histologic ﬁbrosis stage assessed using NASH CRN and Ishak scoring systems X X
• Change in hepatic stellate cell activation marker (α-SMA) X X
• Change from Baseline in non-invasive scores and markers of hepatic ﬁbrosis (APRI, FIB-4, hyaluronic acid, FibroTest
[FibroSure], NFS, and ELF)
X X X X
• Change from Baseline in biomarkers of hepatocyte apoptosis, assessed using CK-18 caspase-cleaved and total X X
• Change from Baseline in liver parameters and fasting metabolite parameters X X X X X X
• Change from Baseline in weight, BMI, waist circumference, waist–hip ratio, arm circumference, and tricep skinfold X X X X X X
Tertiary objectives
• Change from Baseline in non-invasive liver imaging method (e.g. TE, MRE, and ARFI)d X X X X
• Change from Baseline in pro-inﬂammatory cytokines and biomarkers of inﬂammation X X X X X X
• Change from Baseline in eGFR X X X X X X
• Change from Baseline in biomarkers associated with bacterial translocation X X X X X X
α-SMA,α-smoothmuscle actin; APRI, aspartate aminotransferase-to-platelet count ratio index; ARFI, acoustic radiation force impulse; BMI, bodymass index; CPA, collagen proportionate
area; CRN, clinical research network; CVC, cenicriviroc; ELF, enhanced liver ﬁbrosis test; eGFR, estimated glomerular ﬁltration rate; FIB-4, non-invasive hepatic ﬁbrosis risk score; MRE, 2-
dimensional magnetic resonance elastography; NAS, non-alcoholic fatty liver disease activity score; NASH, non-alcoholic steatohepatitis; NFS, non-alcoholic fatty liver disease ﬁbrosis
score; PK, pharmacokinetics; TE, ultrasound transient elastography.
a Worsening deﬁned as progression of NASH CRN ﬁbrosis stage.
b Histopathologic interpretation of no fatty liver disease or simple or isolated steatosis with no steatohepatitis.
c Plasma samples for population PK analysis will be collected on Day 1 (Baseline) and Months 0.5, 3, 6, 12, 15, 18, and 24.
d At sites where available.
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IRB/IEC requirements will be followed during the study and after its
completion.3.2. Eligibility process
The subjects recruited in this study will need to satisfy the following
histological criteria, read by a central pathologist: presence of
steatohepatitis (NASH), NAS ≥ 4, and presence of ﬁbrosis Stages 1–3 ac-
cording to the NASH CRN system. They will also be at increased risk of
disease progression due to one ormore of the following: documented ev-
idence of T2DM, high bodymass index (BMI N 25 kg/m2)with at least one
of the criteria of themetabolic syndrome, as deﬁned by the National Cho-
lesterol Education Program (NCEP), bridging ﬁbrosis (NASH CRN Stage
3) and/or deﬁnite NASH (NAS ≥ 5). The detailed inclusion and exclusion
criteria for subject eligibility are shown in Tables 3 and 4, respectively.Table 2
Sample size prediction calculations.
Placebo,
N
CVC treatment,
N
Placebo
response (%)
CVC treatment
response (%)
Difference in
response (%)
Powera
(%)
140 140 16 36 20 96
140 140 18 36 18 91
140 140 20 36 16 82
140 140 20 38 18 90
140 140 20 40 20 95
CVC, cenicriviroc.
a Power calculated using Fisher's exact test with response for placebo ranging from 16
to 20% and for CVC treatment from 36 to 40%, and differences in response from 16 to 20%.3.3. Prior and concomitant therapy
CVC is a known substrate of CYP2C8, CYP3A4, and P-glycoprotein,
and aweak inhibitor of CYP3A4; therefore, the following classes ofmed-
ication are disallowed/excluded:
• CYP3A4 — inhibitors/inducers
• CYP2C8 — inhibitors
• sensitive CYP3A4 substrates (e.g. drugs that should not be co-
administered with weak CYP3A4 inhibitors, such as CVC)
• P-glycoprotein and breast cancer resistance protein – substrates and
inhibitors/inducers
• other medications that may have confounding effects on CVC efﬁcacy.
Pioglitazone, rosiglitazone, vitamin E N 400 IU/day, S-adenosyl-
methionine, pentoxifylline, and ursodiol are disallowed due to possible
confounding effect on efﬁcacy.
Other disallowed medications that are commonly administered to
subjects with NASH include the antidiabetic agent saxagliptin, the
lipid-lowering agents gemﬁbrozil and rosuvastatin, and the antihyper-
tensive agents aliskiren, captopril, carvedilol, diltiazem, verapamil, and
felodipine.
Medications that are CYP3A4 substrates (e.g. the lipid-lowering
agents atorvastatin, simvastatin, pravastatin, and lovastatin) can be
used as concomitant treatments in this study, but clinical monitoring
and dose titration are recommended to achieve the desired clinical re-
sponse: CVC is aweakCYP3A4 inhibitor and, therefore,may increase ex-
posure of these medications. Other medications that can be used with
caution are intravenous midazolam, alfentanil or fentanyl, and systemic
corticosteroids. Antacids, H2-receptor antagonists and proton-pump
Table 3
CENTAUR inclusion criteria.
Criteria type Description of inclusion criteria
Sex and age Males and females; 18–75 years of age
Histological evidence of NASH Based on Screening biopsy, with a NAS of
≥4 with at least 1 point in each
component of NAS
Histological evidence of liver ﬁbrosis Based on Screening biopsy, deﬁned as
NASH CRN system stages 1–3 inclusive
Increased risk of disease progression Meeting any of the following criteria:
• documented evidence of T2DM
• high BMI (N25 kg/m2) with at least one
criteria of the metabolic syndromea
• bridging ﬁbrosis (NASH CRN stage 3)
and/or deﬁnite NASH (NAS ≥5)
AST and ALT levels ≤5× ULN
Serum albumin levels ≥3.5 g/dL
eGFR ≥50 mL/min/1.73 m2 (according to the
MDRD equation)
Platelet count ≥100 000/mm3
Informed consent Ability to understand and sign a written
informed consent form
Use of concomitant medications Subjects need to be on stable therapy for
30 days prior to the Baseline visit
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
CRN, clinical research network; eGFR, estimated glomerular ﬁltration rate;MDRD,modiﬁ-
cation of diet in renal disease; NAS, non-alcoholic fatty liver disease activity score; NASH,
non-alcoholic steatohepatitis; T2DM, type 2 diabetesmellitus; ULN, upper limit of normal.
a Criteria of the metabolic syndrome, as deﬁned by the National Cholesterol Education
Program, are: central obesity, waist circumference ≥ 102 cm or 40 in. (male), ≥88 cm
or 35 in. (female); dyslipidemia, triglyceride ≥ 1.7 mmol/L (150 mg/dL); dyslipidemia,
high-density lipoprotein-cholesterol b40mg/dL (male), b50mg/dL (female); blood pres-
sure ≥ 130/85mmHg (or treated for hypertension); fasting plasma glucose ≥6.1 mmol/L
(110 mg/dL).
Table 4
CENTAUR exclusion criteria.
Criteria type Description of exclusion criteria
Liver co-morbidities • History of cirrhosis and/or hepatic decompensatio
• HBsAg positive
• HCVAb positive, with two exceptions if all other e
Subjects previously treated for viral hepatitis C w
12 (post-treatment)
Subjects with the presence of HCVAb but negati
• Other known causes of chronic liver disease, inclu
• Prior or planned liver transplantation
Other co-morbidities • Clinically signiﬁcant cardiovascular or cerebrovasc
infarction, acute coronary syndrome, revasculariza
• Any Grade ≥ 3 laboratory abnormalitya, with excep
Subjects with pre-existing diabetes or with asym
Subjects with Grade ≥ 3 dyslipidemia with trigly
Subjects with asymptomatic Grade ≥ 3 creatine
• HIV-1 or HIV-2 infection
• History of malignancy within the past 5 years or o
cutaneous squamous-cell carcinoma
• Active, serious infections that require parenteral a
Lifestyle • Alcohol consumption N 21 units/week for males or
• Positive urine screen for amphetamines, cocaine, o
amphetamines for co-morbidities
Concomitant treatments • Weight reduction through bariatric surgery in the
• Current or anticipated treatment with radiation th
• Receiving ongoing therapy with any disallowed m
• Receiving any experimental medications within 30
Other • Females who are pregnant or breastfeeding
• Allergy to the study drug or its components
• Participation in any other clinical trial at Screening
• Any other clinically signiﬁcant disorders or prior th
the dosing and protocol requirements
HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C virus antibody; HIV, human immunode
a As deﬁned by the National Cancer Institute Common Terminology Criteria for Adverse Eve
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study drug, as CVC absorption is enhanced with low gastric pH [42].3.4. Randomization
Eligible subjects will be assigned to either CVC treatment or placebo
at Day 1 (Baseline) using permuted block randomization stratiﬁed by
NAS at Screening (4 or ≥5) and ﬁbrosis stage (≤2 or N2). Subjects will
be randomized in a 2:1:1 ratio to CVC 150 mg once daily (QD) for
2 years (Arm A), placebo QD for 1 year then CVC 150 mg QD for
1 year (Arm B), or placebo QD for 2 years (Arm C), as shown in Fig. 2.3.5. Study drug administration and blinding
Subjects will be instructed to take one tablet (CVC or matching pla-
cebo) every morning with food for 2 years of treatment. The subjects,
sponsor, investigators, and personnel involved in the study will be
blinded to the individual assignments of CVC and placebo until all sub-
jects have completed the 2-year study and the database has been locked
for all study data. The sponsor will provide CVC and matching placebo
that are visually indistinguishable in order to ensure blinding of these
products.4. Study procedures
The schedule of assessments for the studyprocedures is summarized
in Table 1.n including ascites, hepatic encephalopathy, or variceal bleeding
ligibility criteria are met.
ith at least a 1-year period since documented sustained virologic response at Week
ve hepatitis C virus RNA without treatment (i.e. spontaneous clearance)
ding alcoholic liver disease
ular disease within the past 3 months, including, but not limited to, myocardial
tion or ischemic stroke, or implanted deﬁbrillator or pacemaker
tions unless clinical assessment foresees an immediate health risk
ptomatic glucose elevations
ceride or cholesterol elevations
kinase elevations
ngoing malignancy other than basal-cell carcinoma, or resected non-invasive
ntibiotic or antifungal therapy within 30 days prior to Screening visit
N14 units/week for females
r opiates at Screening, with the exception of medical treatment with opiates or
past 5 years or planned during the conduct of the study
erapy, cytotoxic chemotherapeutic agents or immunomodulating agents
edication from Screening onwards
days prior to Screening or anticipated use during the trial
without approval from the Sponsor
erapy that would make the subject unsuitable for the study or unable to comply with
ﬁciency virus.
nts (NCI CTCAE) version 4.03 Toxicity Grading Scale.
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At Screening, informed consent will be obtained and eligibility for
the studywill be conﬁrmed. Eligibilitywill be analyzed by obtaining de-
mographic information,medical history, and a liver biopsy, undertaking
safety evaluations (as described in safety assessments), performing a
urine drug screen and drawing blood to determine any presence of
HIV-1 or -2 antibodies, hepatitis B surface antigen and/or hepatitis C
virus antibody. The liver biopsy will be read by a central pathologist,
blinded to treatment, and used to assess NAS, histologic ﬁbrosis stage
(NASH CRN and Ishak scoring systems), collagen morphometry (colla-
gen proportionate area [CPA]) andα-SMA. An historical biopsy (obtain-
ed ≤180 days prior to Screening) can be used if the subjects were
metabolically stable following the procedure and have had nonew ther-
apeutic intervention for NASH. Year 1 and 2 biopsies will be performed
within 1 month prior to the end of the respective year, and all efforts
will be made to obtain a Year 1 liver biopsy for each study subject to
allow comparison with the Year 2 biopsy. In the event that obtaining a
liver biopsy at Year 1 is not feasible, subjects will be allowed to proceed
to Year 2 and will subsequently undergo liver biopsy at the end of Year
2. Subjects with missing post-baseline biopsies will be imputed as non-
responders for Year 1 and 2 primary and key secondary efﬁcacy end-
points. Additional imputationmethodswill be utilized to perform sensi-
tivity analyses. These biopsies will be centrally read by the same expert
pathologist blinded to treatment, for assessment of primary and sec-
ondary histological outcomes.
4.2. Safety assessments
The following safety evaluationswill be undertaken for every subject
visit from Screening until 1-month follow-up (shown in Table 1): as-
sessment of adverse events (AEs) and concomitant medication use,
physical examination, vital-signs measurements, hematology and
serum chemistry laboratory tests, urinalysis, and urine pregnancy
tests. BMI determination and estimated glomerular ﬁltration rate
(eGFR) will also be assessed at Screening and in Months 0 (Baseline),
3, 6, 12, 15, 18, and 24. The following safety evaluations will also be
undertaken for Months 0, 3, 6, 12, 15, 18, and 24: 12-lead electro-
cardiogram (ECG),measurement of biomarkers of hepatocyte apoptosis
(CK-18), inﬂammation and bacterial translocation, and fastingmetabol-
ic parameters.
4.3. Physical assessments, measurements, and laboratory tests
A complete physical examination will be undertaken at Screening
and Baseline. Furthermore, a symptom-directed physical examination
will be performed as needed for every subject visit from Screening
until 1-month follow-up. Vital signs will be performed with the subject
in the seated position, after 5 min of rest, and before any blood draws.Table 5
Classiﬁcations of AE intensity [43].
AEs will be graded according to the criteria in this table, which is from the NCI CTCAE ver-
sion 4.03 Table for Grading the Severity of Adult Adverse Events.
Grade Description
Grade 1 (mild) Asymptomatic or mild symptoms; clinical or diagnostic
observations only; intervention not indicated
Grade 2 (moderate) Minimal, local or non-invasive intervention
indicated; limiting age-appropriate instrumental ADL
Grade 3 (severe) Medically signiﬁcant but not immediately
life-threatening; hospitalization or prolongation of
hospitalization indicated; disabling; limiting self-care ADL
Grade 4 (life-threatening) Life-threatening consequences; urgent intervention
indicated
Grade 5 (death) Death related to AE
ADL, activities of daily living; AE, adverse event; CTCAE, Common Terminology Criteria for
Adverse Events; NCI, National Cancer Institute.Urinalysis will be undertaken and analyzed using standard procedures
by a central laboratory, and will include determination of urine albu-
min/creatinine ratio and urine β2-microglobulin. Urine pregnancy
tests will be undertaken using a dipstick method. Hematology and
serum chemistry laboratory tests will be performed by a central labora-
tory using standard procedures, and any abnormal results that are pos-
sibly related to study drug treatment will be reported weekly until the
abnormality is resolved or is otherwise explained. At Screening, the
height and weight of subjects will be measured to calculate BMI, and
subsequently the waist circumference, hip circumference, arm circum-
ference, and triceps skinfoldwill also bemeasured. The eGFRwill be cal-
culated by the central laboratory using theModiﬁcation of Diet in Renal
Disease formula, the Cockcroft-Gault equation, the Chronic Kidney Dis-
ease Epidemiology Collaboration formula (based on cystatin C [mg/L]
and serum creatinine), and adjusted for age, sex, and race. ECGs will
be performed with the subject in the supine position, after 5 min of
rest, and before any blood draws. Biomarkers of hepatocyte apoptosis,
inﬂammation and bacterial translocation, and fasting metabolic param-
eters will be undertaken by a central laboratory.
4.4. Adverse events
All AEs during the study will be recorded in the electronic case-
report form, with information about the date of onset and end date
(if applicable), severity and seriousness of the AE, investigator's opinion
of the relationship to CVC treatment, action taken regarding CVC usage
and treatment for AE, cause of event (if known), and information re-
garding the resolution or outcome. AEs classiﬁed as serious will be re-
corded on a serious-adverse-event reporting tool and reported to the
sponsor. The intensity of an AE will be graded according to the National
Cancer Institute's Common Terminology Criteria for Adverse Events
(NCI CTCAE) version 4.03, which includes the classiﬁcations of AE inten-
sity shown in Table 5.
4.5. Pharmacokinetic analyses
Plasma samples for population PK analysis will be collected accord-
ing to the schedule stated in Table 1. For each study visit, all subjects
will take their daily dose during the visit under witnessed dosing. At
Months 0.5, 3, and 15, one pre-dose sample and one post-dose sample
will be collected; on all other visits one pre-dose sample will be collect-
ed. A plasma sample for PKwill also be taken, preferablywithin 24–48 h
of the last dose of study drug if a subject discontinues the treatment
early due to an AE.
4.6. Other study procedures
For the study visits at Months 0, 3, 6, 12, 15, 18, and 24, subjects
must have fasted for at least 8 h prior to the visit. Those who have
not fasted will be required to return after fasting within 72 h and
before blood is drawn for metabolic assessments. Subjects who dis-
continue study treatment before the 2 years will attend an early dis-
continuation visit within 48 h of withdrawal. Follow-up evaluations
will be conducted on subjects approximately 1 month after their last
dose of study drug, including those who discontinue the treatment
early. A liver biopsy will be performed within 1 month of discontinua-
tion, if possible, from subjects who have received treatment with the
study drug (CVC or placebo) for at least 6 months during Year 1 or
Year 2.
4.7. Criteria for discontinuation of study treatment
Study treatment must be discontinued in cases of suspected drug-
induced liver injury, unacceptable toxicity, acute viral hepatitis types
A, B, C, D, or E, autoimmune or alcoholic hepatitis, hypoxic or ischemic
hepatopathy, biliary tract diseases, or pregnancy. Treatment would
363S. Friedman et al. / Contemporary Clinical Trials 47 (2016) 356–365also cease if the subject requests discontinuation or if the study is
discontinued.
5. Outcome measures
5.1. Efﬁcacy evaluation
The efﬁcacy endpoints for this study are shown in Fig. 3.
5.2. CVC PK evaluation
The population PK endpoints in this study include the characteriza-
tion of the population PK of CVC in subjects with NASH, and prediction
of plasma CVC exposure over the duration of the study. A further popu-
lation PK endpoint to be evaluated is the covariates that impact CVC PK
(e.g. age, sex, weight, BMI, race, ﬁbrosis stage).
5.3. Safety evaluation
The safety and tolerability of CVC will be evaluated over the 2 years
of treatment in subjects with NASH. This will include the evaluation of
AEs, clinical laboratory tests, physical examination, vital signs, and 12-
lead ECG. The clinical laboratory tests will include liver and fastingmet-
abolic parameters. Liver parameters will include alkaline phosphatase,
alanine aminotransferase, serum albumin, aspartate aminotransferase,
direct bilirubin, total bilirubin, and gamma-glutamyl transferase.
5.4. Statistical analyses
The primary efﬁcacy endpoint will be analyzed by comparing CVC
(treatment Arm A) versus placebo (combined treatment Arms B and
C) treatment groups at the end of Year 1 (Fig. 2) for all randomized sub-
jects who received at least one dose of study drug and had ameasurable
Screening biopsy. The sample size for the primary endpoint was based
on the primary binary endpoint comparing treatment Arm A versus
combined treatment Arms B and C. This comparison will be performed
using logistic regression, with the Cochran–Mantel–Haenszel test used
for sensitivity analysis, and stratiﬁcation will be based on the randomi-
zation strata. Treatment differences will be assessed and include esti-
mates and 95% conﬁdence intervals for the stratiﬁcation adjusted
difference between the response rates for CVC and placebo and the
stratiﬁcation adjusted odds ratio for the comparison between CVC and
placebo. Subjects with missing post-baseline biopsies will be imputed
as non-responders for Year 1 and 2 primary and key secondary efﬁcacy
endpoints. Additional imputation methods will be utilized to perform
sensitivity analyses. However, subjects that discontinue early who
have had N6 months of treatment in Year 1 or 2 will be included in
the efﬁcacy analysis if a biopsy can be obtained within 1 month of dis-
continuation. A sensitivity analysis will be performed for all subjectsFig. 4. CENTAUR treatment group comparisons in Years 1 and 2. The main efﬁcacy endpoints
endpoints in Years 1 and 2 are shown in the right panel. α-SMA, α-smooth muscle actin; CP
activity score; NASH, non-alcoholic steatohepatitis.with available biopsy data. If the primary endpoint is achieved with sta-
tistical signiﬁcance, the key secondary endpoint will be tested using lo-
gistic regression, with a similar Cochran–Mantel–Haenszel test used for
sensitivity analysis. Analysis of endpoints at Year 2 will mainly compare
subjects who are randomized to and treated with CVC or placebo for
2 years (i.e. Arms A and C; Fig. 4).
Secondary efﬁcacy endpoints will be described using both descrip-
tive statistics and two-sided 95% conﬁdence intervals for observed data.
A population PK analysis of CVC will be performed using pre-dose
and randomPK samples collected throughout the study.Measured plas-
ma CVC concentrationswill be used to conduct non-linearmixed effects
modeling of population PK. Subject covariates will be analyzed and ex-
ploratory exposure-response (PK/PD) analysesmay be conducted on ef-
ﬁcacy and/or safety endpoints of interest.
The occurrence of treatment-emergent AEs will be summarized by
treatment group usingMedical Dictionary for Regulatory Activities pre-
ferred terms, system-organ classiﬁcations, and severity. Clinical labora-
tory tests will be presented as descriptive summaries by study visit.
Laboratory abnormalitieswill be graded according to NCI CTCAE version
4.03. The number and percentage of subjects that experience
treatment-emergent graded toxicitieswill be summarized by treatment
group and severity grade. Laboratory toxicity shifts from Baseline to
post-Baseline assessments and changes from Baseline in laboratory
tests will be summarized for each treatment group. Any abnormal ﬁnd-
ings considered clinically signiﬁcantwill be recorded as AEs, or noted as
medical history if already present at Screening. Results of ECGs will be
reviewed for clinically notable abnormalities according to predeﬁned
criteria, and patients exhibiting Grade 3 or 4 PR or QTc interval will be
summarized. The number and percentage of subjects taking concomi-
tant medications will be summarized using World Health Organization
preferred terms and drug classiﬁcations.
6. Discussion
The key endpoints of CENTAUR are based on those initially proposed
by the AASLD in 2011, and later discussed in a joint meeting between
the AASLD and the FDA in 2013, and those used in the PIVENS, FLINT
and GOLDEN studies [35–37,39,44]. Liver histology endpoints, such as
complete resolution of NASH, are considered surrogates for preventing
cirrhosis (i.e. they are thought to predict clinical beneﬁt, but are not di-
rectmeasures of it) [36]. However, considering thatmorbidity andmor-
tality are endpoints that would require a large time frame and sample
size to determine, these surrogates provide short-term methods that
are reasonably likely to predict clinical beneﬁt in preventing cirrhosis
and liver-related death. The primary endpoint, “drop in NAS by ≥2
with at least a 1-point improvement in more than 1 category and with
no concurrent worsening of ﬁbrosis stage (Year 1)”, has the advantage
of being measurable, sensitive to change and treatment effect, and can
be quantiﬁed consistently [35,36]. However, the degree to whichare listed in the left panel. The treatment groups that will be compared for these efﬁcacy
A, collagen proportionate area; CVC, cenicriviroc; NAS, non-alcoholic fatty liver disease
364 S. Friedman et al. / Contemporary Clinical Trials 47 (2016) 356–365improvement in NAS correlates with a clinically signiﬁcant decrease in
the risk of cirrhosis or mortality, or the degree to which different com-
ponents of NAS affect the development of cirrhosis, remain unknown
[35]. The key secondary endpoint, “complete resolution of NASH (histo-
pathologic interpretation of no fatty liver disease or simple or isolated
steatosis with no steatohepatitis) with no concurrent worsening of ﬁ-
brosis stage (worsening deﬁned as progression of NASH CRN ﬁbrosis
stage) (Year 2)”, is expected to be associated with reduced risk of cir-
rhosis, making it an approvable surrogate endpoint [35,36]. Although
there are limited data to conﬁrm that reversal of steatohepatitis pre-
vents cirrhosis, studies suggest that steatohepatitis is associated with a
substantial long-term risk of developing cirrhosis [7,35,36].
A disadvantage of using histological methods for assessing clinical
beneﬁt is that liver biopsies are invasive, painful, subject to sample var-
iability, and can occasionally lead to serious complications [36]. Current-
ly, the non-invasive markers that are used to assess NASH progression
are not robust enough to replace liver biopsy, but may be useful for
supporting efﬁcacy [35,36]. Various non-invasive markers of NASH pro-
gression (Table 1) will be included as secondary endpoints to allow
comparison against the histological endpoints.
The study population in CENTAUR has been enriched to select for
subjects with NASH and liver ﬁbrosis (i.e. at higher risk of progres-
sion to cirrhosis), and there is broad consensus that those with the
greatest risk of cirrhosis are particularly important to target [35].
Therefore, the inclusion criteria contain presence of ﬁbrosis and
risk factors for ﬁbrosis progression, including presence of
steatohepatitis, T2DM, and high BMI (Table 3) [7,35,36,45]. Since
the majority of NASH patients will not progress to cirrhosis, it is im-
portant to reduce the heterogeneity of the study population, yet have
a large enough histological spectrum to allow the ﬁndings to be rel-
evant for a wide range of subjects with NASH [36]. This disadvantage
of a heterogeneous study population was a feature of the GOLDEN
study, where subjects with early NASH had an unexpectedly high
rate of NASH resolution in the placebo group, and the primary end-
point of the study could only be met after correcting for baseline se-
verity [44]. Using a high-risk population with early-stage NASH and
ﬁbrosis in CENTAUR will reduce the heterogeneity in the study
groups, allowing the detection of a greater difference between CVC
treatment and placebo. In contrast, the PIVENS, FLINT and GOLDEN
studies included subjects mostly based on the presence of
steatohepatitis and NAS score, and neither required liver ﬁbrosis
for eligibility nor enriched for other risk factors associated with ﬁ-
brosis progression [37,39,44]. CENTAUR will also allow the assess-
ment of the safety and tolerability of CVC in a larger population of
subjects with NASH. CENTAUR is the ﬁrst study that has speciﬁcally
targeted subjects at higher risk of cirrhosis, who are likely to beneﬁt
most from improvement in NASH and prevention of ﬁbrosis
progression.
7. Summary
CENTAUR is a Phase 2b, randomized, double-blind, placebo-
controlled, multinational study for the treatment of NASH and liver ﬁ-
brosis. The study will evaluate the efﬁcacy and safety of CVC 150 mg
over 2 years with a primary endpoint at Year 1. The primary endpoint
of this study is the histological improvement in NAS at Year 1 relative
to Screening biopsy, with no worsening of ﬁbrosis stage. The key sec-
ondary endpoint, which is the complete resolution of NASH with no
concurrentworsening ofﬁbrosis stage, a suitable endpoint for accelerat-
ed approval, will be analyzed at Year 2. Of 812 subjects screened, 289
were enrolled in 11 countries (166 in the USA, 94 in the European
Union, 29 in the Asia-Paciﬁc region). Results of this study will allow
the comparison of the beneﬁts of shorter versus longer treatment with
CVC, the correlation between improvement in inﬂammation and ﬁbro-
sis, and evaluation of the progression of NASH at Year 1 and 2 in the pla-
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